The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,951.00
Bid: 1,948.00
Ask: 1,950.00
Change: -8.00 (-0.41%)
Spread: 2.00 (0.103%)
Open: 1,942.00
High: 1,951.00
Low: 1,938.00
Prev. Close: 1,959.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Admiral Rises After Strong Half-Year Results

Wed, 15th Aug 2018 10:40

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.----------FTSE 100 - WINNERS----------Admiral Group, up 5.0%. The motor and home insurer reported an increased interim profit driven by a good performance its UK Motor division, prompting a 7% dividend hike. Admiral posted a 9.1% increase in pretax profit to GBP211.0 million from GBP193.4 million a year before. Revenue increased 14% to GBP1.66 billion from GBP1.45 billion. Return on equity fell to 54% from 55% in the same period last year. Admiral saw an 11% profit increase in its UK Motor division, to GBP249.5 million from GBP224.2 million, in the period, mainly as a result of "growth in ancillary revenue and installment income". The company is proposing an interim dividend of 60.0 pence per share, a 7.1% increase year-on-year from 56.0p paid a year previously.----------GlaxoSmithKline, up 1.5%. The drugmaker said its majority-owned HIV specialist company ViiV Healthcare saw positive headline results from its phase III antiretroviral therapy as long-acting suppression study for the treatment of human immunodeficiency virus. Glaxo said the study showed long-acting cabotegravir and rilpivirine, injected once a month, had similar efficacy to a standard of care, daily, oral three-drug regimen at Week 48. The injectable treatment regimen met the primary endpoint for non-inferiority, Glaxo said. Overall safety, virologic response and drug resistance results for the injectable regimen were consistent with results from the phase II LATTE and LATTE-2 studies.----------FTSE 100 - LOSERS----------Fresnillo, down 2.9% and Randgold Resources, down 2.5%. The gold miners were tracking spot gold prices lower quoted at USD1,186.69 an ounce compared to USD1,196.85 at the London equities close Tuesday as the precious metal traded around its worst levels since January 2017.----------BHP Billiton, down 2.0%, Glencore, down 1.9%, Antofagasta, down 1.8%, Anglo American, down 1.7%, Rio Tinto, down 1.6%. The miners were lower amid a strengthening dollar and lower copper prices. "The price of copper has this week hit a 13-month low following a sharp slowdown in China's fixed-asset investment growth. This news, together with waning investor appetite for riskier assets, has unsurprisingly put a dent in the mining sector," said AJ Bell's Russ Mould. Midcap peer Kaz Minerals was down 3.6%.----------FTSE 250 - WINNERS----------Hikma Pharmaceuticals, up 8.5%. The drugmaker raised its annual revenue target for its Injectables and Generics divisions following a significant uplift in profit in the first half of 2018. Hikma said pretax profit for the six months to the end of June totalled USD141.0 million, up from USD100.0 million reported for the same period a year earlier, as revenue climbed 11% to USD989.0 million from USD895.0 million. On a constant currency basis, revenue rose by 10%. Hikma raised its full-year guidance for the Injectables unit and now expects revenue for 2018 to come in between USD775 million and USD825 million. Previously, Hikma targeted the Injectables division to achieve revenue growth in a range of USD750 million to USD800 million. The company declared an interim dividend of 12 cents per share, up from 11 cents paid the year before. ----------Balfour Beatty, up 3.6%. The infrastructure company reported a drop in interim revenue but increased profit, boosting its interim payout as a result. Balfour said pretax profit rose to GBP50 million from just GBP12 million the year before. Revenue decreased 9.4% to GBP3.84 billion from GBP4.20 billion. The company's underlying pretax profit increased to GBP52 million from GBP23 million. The company said a reduction in overhead costs to GBP11 million from GBP18 million led to increased profitability. Balfour is proposing an interim dividend increase of 33% to 1.6p per share from 1.2p last year. Looking ahead, the company expects its second half revenue to be in line with the first half. Balfour expects to achieve its underlying profit from operations margin targets in the second half. ----------FTSE 250 - LOSERS----------CLS Holdings, down 2.2%. The property investor reported a rise in interim net asset value as well as solid growth in net rental income for the period. Basic net asset value at the end of the period was 260.2 pence, 3.3% higher than the figure at the end of December, while EPRA net asset value was 3.0% higher at 294.7p. CLS's net rental income rose 8.7% year-on-year to GBP55.0 million, while its vacancy rate fell to 5.7% from 5.8%. Pretax profit for the period was GBP64.9 million, down year-on-year from GBP119.4 million, due to lower property valuation changes as well as the fact the comparable had a significantly higher property sale gain. Looking forward, the company said it is focusing partly on making investments in Germany and the south-east of the UK. The UK as a whole, however, is likely to remain subdued to to Brexit, but Germany and France are benefiting from strong property demand and a limit on new office space.----------OTHER MAIN MARKET AND AIM - WINNERS----------Feedback, up 22%. The medical imaging technology company said its subsidiary has secured its first order for image texture analysis technology TexRAD via GE Healthcare. Feedback said the order follows the distribution agreement, which allows medical technologies & services provider GE Healthcare non-exclusively offer TexRAD for medical imaging research applications. The new order came from the Post Graduate Institute of Medical Education & Research, located in Chandigarh, India. Feedback said its software is currently used in over 50 of the world's leading research institutions across Europe, North America, Asia and Australasia.----------
More News
22 Feb 2024 09:42

TOP NEWS: Hikma boosts dividend after year of "significant progress"

(Alliance News) - Shares in Hikma Pharmaceuticals PLC jumped on Thursday after it lifted the dividend by 29% amid better-than-expected annual profit.

Read more
22 Feb 2024 07:51

Hikma lifts dividend after double-digit growth in 2023

(Sharecast News) - Hikma Pharmaceuticals impressed the market with its annual results on Thursday as it bumped up its dividend by almost a third following double-digit growth in core revenues and profits in 2023.

Read more
15 Feb 2024 14:42

UK earnings, trading statements calendar - next 7 days

Friday 16 February 
NatWest Group PLCFull Year Results
Segro PLCFull Year Results
TBC Bank Group PLCFull Year Results
Monday 19 February 
Bank of Cyprus Holdings PLCFull Year Results
MoneySupermarket.com PLCFull Year Results
Transense Technologies PLCHalf Year Results
Wilmington PLCHalf Year Results
Tuesday 20 February 
Antofagasta PLCFull Year Results
Barclays PLCFull Year Results
BHP Group LtdHalf Year Results
Coca-Cola Europacific Partners PLCFull Year Results
Gran Tierra Energy IncFull Year Results
InterContinental Hotels Group PLCFull Year Results
Petra Diamonds LtdHalf Year Results
Springfield Properties PLCHalf Year Results
Wednesday 21 February 
BAE Systems PLCFull Year Results
Conduit Holdings LtdFull Year Results
Glencore PLCFull Year Results
HSBC Holdings PLCFull Year Results
Rio Tinto PLCFull Year Results
Riverstone Credit Opportunities Income PLCFull Year Results
Tate & Lyle PLCTrading Statement
Thursday 22 February 
Anglo American PLCFull Year Results
Genus PLCHalf Year Results
Hargreaves Lansdown PLCHalf Year Results
Hays PLCHalf Year Results
Hikma Pharmaceuticals PLCFull Year Results
Indivior PLCFull Year Results
Jupiter Fund Management PLCFull Year Results
Lloyds Banking Group PLCFull Year Results
ME Group International PLCFull Year Results
Morgan Sindall Group PLCFull Year Results
Pantheon International PLCHalf Year Results
Rolls-Royce Holdings PLCFull Year Results
WPP PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
2 Feb 2024 07:23

Hikma agrees to settle US opioid claims

(Sharecast News) - Hikma Pharmaceuticals announced an agreement in principle to address the majority of opioid-related claims filed against it by various US states, local communities and tribal nations on Friday.

Read more
1 Feb 2024 20:00

EARNINGS AND TRADING: Tandem FY sales down 17%; Hikma's opioid deal

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
9 Jan 2024 09:29

LONDON BROKER RATINGS: Berenberg cuts target prices for miners

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Wednesday:

Read more
20 Dec 2023 09:25

LONDON BROKER RATINGS: UBS cuts DS Smith; Kepler likes Genus

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
19 Dec 2023 09:11

LONDON BROKER RATINGS: Peel Hunt raises Flutter to 'buy' from 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
7 Nov 2023 13:08

Jefferies downgrades Hikma to 'hold'

(Sharecast News) - Jefferies downgraded Hikma Pharmaceuticals on Tuesday to 'hold' from 'buy' and cut the price target to 1,940p from 2,125p.

Read more
7 Nov 2023 09:28

LONDON BROKER RATINGS: Watches of Switzerland impresses HSBC; Asos cut

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
7 Nov 2023 07:43

LONDON BRIEFING: AB Foods hails Primark; Beazley premiums rise

(Alliance News) - London's FTSE 100 is called to open in the red on Tuesday, following Asian equities lower, as the good feeling in equity markets after the softer US jobs data on Friday gives way to some caution.

Read more
6 Nov 2023 12:01

Berenberg stays at 'hold' on Hikma Pharmaceuticals

(Sharecast News) - Analysts at Berenberg reiterated their 'hold' rating and 2,100.0p target price on Hikma Pharmaceuticals on Monday, saying a "lighter" second half was playing out in its injectables unit.

Read more
3 Nov 2023 09:31

LONDON BROKER RATINGS: JPMorgan lifts Smith & Nephew

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

Read more
2 Nov 2023 15:12

London close: Stocks rise as BoE keeps rates steady

(Sharecast News) - London's stock markets ended the day on a positive note on Thursday, following the Bank of England's decision to maintain interest rates as markets widely expected.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.